Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo
Standard
Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo. / Ergen, Can; Niemietz, Patricia Maria; Heymann, Felix; Baues, Maike; Gremse, Felix; Pola, Robert; van Bloois, Louis; Storm, Gert; Kiessling, Fabian; Trautwein, Christian; Luedde, Tom; Lammers, Twan; Tacke, Frank.
In: BIOMATERIALS, Vol. 2018, No. 206, 06.2019, p. 49-60.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo
AU - Ergen, Can
AU - Niemietz, Patricia Maria
AU - Heymann, Felix
AU - Baues, Maike
AU - Gremse, Felix
AU - Pola, Robert
AU - van Bloois, Louis
AU - Storm, Gert
AU - Kiessling, Fabian
AU - Trautwein, Christian
AU - Luedde, Tom
AU - Lammers, Twan
AU - Tacke, Frank
N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.
PY - 2019/6
Y1 - 2019/6
N2 - Myeloid immune cells promote inflammation and fibrosis in chronic liver diseases. Drug delivery systems, such as polymers, liposomes and microbubbles, efficiently target myeloid cells in healthy liver, but their targeting properties in hepatic fibrosis remain elusive. We therefore studied the biodistribution of three intravenously injected carrier material, i.e. 10 nm poly(N-(2-hydroxypropyl)methacrylamide) polymers, 100 nm PEGylated liposomes and 2000 nm poly(butyl cyanoacrylate) microbubbles, in two fibrosis models in immunocompetent mice. While whole-body imaging confirmed preferential hepatic uptake even after induction of liver fibrosis, flow cytometry and immunofluorescence analysis revealed markedly decreased carrier uptake by liver macrophage subsets in fibrosis, particularly for microbubbles and polymers. Importantly, carrier uptake co-localized with immune infiltrates in fibrotic livers, corroborating the intrinsic ability of the carriers to target myeloid cells in areas of inflammation. Of the tested carrier systems liposomes had the highest uptake efficiency among hepatic myeloid cells, but the lowest specificity for cellular subsets. Hepatic fibrosis affected carrier uptake in liver and partially in spleen, but not in other tissues (blood, bone marrow, lung, kidney). In conclusion, while drug carrier systems target distinct myeloid cell populations in diseased and healthy livers, hepatic fibrosis profoundly affects their targeting efficiency, supporting the need to adapt nanomedicine-based approaches in chronic liver disease.
AB - Myeloid immune cells promote inflammation and fibrosis in chronic liver diseases. Drug delivery systems, such as polymers, liposomes and microbubbles, efficiently target myeloid cells in healthy liver, but their targeting properties in hepatic fibrosis remain elusive. We therefore studied the biodistribution of three intravenously injected carrier material, i.e. 10 nm poly(N-(2-hydroxypropyl)methacrylamide) polymers, 100 nm PEGylated liposomes and 2000 nm poly(butyl cyanoacrylate) microbubbles, in two fibrosis models in immunocompetent mice. While whole-body imaging confirmed preferential hepatic uptake even after induction of liver fibrosis, flow cytometry and immunofluorescence analysis revealed markedly decreased carrier uptake by liver macrophage subsets in fibrosis, particularly for microbubbles and polymers. Importantly, carrier uptake co-localized with immune infiltrates in fibrotic livers, corroborating the intrinsic ability of the carriers to target myeloid cells in areas of inflammation. Of the tested carrier systems liposomes had the highest uptake efficiency among hepatic myeloid cells, but the lowest specificity for cellular subsets. Hepatic fibrosis affected carrier uptake in liver and partially in spleen, but not in other tissues (blood, bone marrow, lung, kidney). In conclusion, while drug carrier systems target distinct myeloid cell populations in diseased and healthy livers, hepatic fibrosis profoundly affects their targeting efficiency, supporting the need to adapt nanomedicine-based approaches in chronic liver disease.
U2 - 10.1016/j.biomaterials.2019.03.025
DO - 10.1016/j.biomaterials.2019.03.025
M3 - SCORING: Journal article
C2 - 30925288
VL - 2018
SP - 49
EP - 60
JO - BIOMATERIALS
JF - BIOMATERIALS
SN - 0142-9612
IS - 206
ER -